Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation
Latest Information Update: 04 Jun 2014
Price :
$35 *
At a glance
- Drugs YSPSL (Primary)
- Indications Delayed graft function
- Focus Therapeutic Use
- Sponsors Ys Therapeutics
- 04 Jun 2014 New trial record